ruvector/examples/dragnes/docs/competitive-analysis.md

DrAgnes Competitive Analysis

Status: Research & Planning Date: 2026-03-21

Market Overview

The AI dermatology market is projected to reach $2.8 billion by 2030 (CAGR ~22%). Key drivers include rising skin cancer incidence, dermatologist shortage (US faces a projected shortfall of 10,000+ dermatologists by 2035), and smartphone proliferation enabling mobile health.

The market is currently fragmented across consumer apps (SkinVision, Google), clinical platforms (MetaOptima, Canfield), and FDA-cleared devices (3Derm). No single platform combines collective learning, offline capability, dermoscopy-native design, and cryptographic provenance.

Competitor Profiles

1. SkinVision

• Type: Consumer mobile app (iOS/Android)
• Approach: Smartphone camera photo (no dermoscopy)
• AI Model: Proprietary CNN (not disclosed)
• Regulatory: CE marked (EU Class IIa medical device), not FDA cleared
• Pricing: Subscription (approximately $10/month or $50/year)
• Market: Consumer direct, some B2B insurance partnerships
• Data: 6M+ photos analyzed (claimed)

Strengths:

• Large consumer user base
• Simple UX (point and shoot)
• Insurance partnerships (Netherlands, Australia)
• CE marking provides regulatory credibility

Weaknesses:

• No dermoscopy support (clinical photo only, significantly lower accuracy)
• Static model (does not learn from use)
• Consumer-grade (not positioned for clinical workflow)
• No EHR integration
• Privacy model unclear (images uploaded to cloud)
• No collective learning across users
• Sensitivity for melanoma: approximately 80-85% (vs. >95% target for DrAgnes with dermoscopy)

2. MoleMap

• Type: Clinical skin mapping service (clinics + teledermatology)
• Approach: Whole-body photography + dermatoscopy at dedicated clinics
• AI Model: AI-assisted triage (details not public)
• Regulatory: Clinical service (not a standalone device)
• Pricing: $300-600 per full-body mapping session
• Market: Australia, New Zealand, UK, Ireland
• Coverage: 40+ clinics across ANZ

Strengths:

• Established clinical brand (20+ years)
• Whole-body photography with longitudinal tracking
• Dermatologist review of every case
• Strong in high-incidence regions (Australia, New Zealand)

Weaknesses:

• Requires physical clinic visit (not mobile)
• Expensive per session
• Limited geographic coverage
• AI is assistive only, not well-documented
• No offline capability
• Proprietary closed ecosystem
• No collective learning across clinics

3. MetaOptima / DermEngine

• Type: Clinical AI platform for dermatologists
• Approach: Cloud-based dermoscopic image analysis + teledermatology
• AI Model: Deep learning classifiers (multiple architectures)
• Regulatory: Health Canada Class II, CE marked, not FDA cleared (as of 2026)
• Pricing: SaaS subscription (approximately $200-500/month per practice)
• Market: Canada, EU, expanding to US
• Features: Total body photography, lesion tracking, AI classification, teledermatology

Strengths:

• Comprehensive clinical platform
• Total body photography with AI-powered lesion tracking
• Teledermatology workflow
• EHR integration (select systems)
• Strong in Canada

Weaknesses:

• Cloud-dependent (no offline capability)
• No FDA clearance for US market
• Static models (periodic retraining, not continuous learning)
• No collective learning across practices
• No cryptographic provenance
• No WASM browser inference
• Privacy relies on standard cloud security (no differential privacy)

4. Canfield Scientific

• Type: Medical imaging systems (hardware + software)
• Approach: Professional-grade imaging equipment + IntelliStudio software
• Products: VEOS (dermoscopy), VECTRA (3D body mapping), IntelliStudio (AI analysis)
• Regulatory: FDA cleared (imaging systems, not AI classification)
• Pricing: Hardware $10,000-50,000+ per system; software subscription additional
• Market: Academic medical centers, high-end dermatology practices

Strengths:

• Gold-standard imaging quality
• 3D body mapping (VECTRA WB360)
• Established in research/academic settings
• Strong clinical validation literature
• FDA-cleared imaging hardware

Weaknesses:

• Extremely expensive (inaccessible to primary care)
• Hardware-dependent (no mobile/portable option)
• AI capabilities lagging behind pure-AI companies
• No collective learning
• No offline AI inference
• Proprietary ecosystem (vendor lock-in)

5. Google Health Dermatology AI

• Type: Research project / potential product
• Approach: Smartphone clinical photos (Google Lens integration)
• AI Model: Deep learning on large proprietary datasets (Nature Medicine 2020 publication)
• Regulatory: Not FDA cleared. Labeled as "information only" in Google Search
• Pricing: Free (integrated into Google Search/Lens)
• Market: Global consumer (billions of Google users)

Strengths:

• Massive distribution (Google Search/Lens)
• Enormous training datasets (Google scale)
• Strong research team (published in Nature Medicine)
• Free to end users
• Multilingual support

Weaknesses:

• Not a medical device (no regulatory clearance, no clinical use)
• Clinical photo only (no dermoscopy)
• Consumer-grade accuracy (sensitivity ~80% for melanoma in initial studies)
• No clinician workflow integration
• Privacy concerns (Google data practices)
• No offline capability
• No collective learning (Google learns, but users do not benefit from each other)
• No provenance or auditability
• Cannot be used for clinical decision-making

6. 3Derm (Fotodigm Inc.)

• Type: FDA-cleared AI for skin cancer detection
• Approach: Smartphone-based image capture with AI classification
• AI Model: CNN-based classification
• Regulatory: FDA 510(k) cleared (DEN200069, September 2021) -- one of the first
• Pricing: Not public (enterprise sales)
• Market: US clinical settings
• Clearance: "Aid in detecting skin cancer and other skin conditions in patients"

Strengths:

• FDA cleared (critical competitive advantage)
• Established regulatory pathway (predicate device for future submissions)
• Clinical positioning (for healthcare professionals)
• First-mover in FDA-cleared AI dermatology

Weaknesses:

• Limited to clinical photography (no dermoscopy integration documented)
• Small market presence
• No collective learning
• No offline capability
• Limited public information on accuracy metrics
• No provenance/witness chain

7. Mela Sciences / MelaFind (STRATA Skin Sciences)

• Type: FDA-cleared multispectral analysis device
• Approach: Dedicated hardware device with multispectral imaging (10 wavelengths)
• Regulatory: FDA PMA approved (2011) -- Class III
• Status: Commercially underperformed; STRATA pivoted to psoriasis/vitiligo treatment
• Pricing: $7,500 device + $150/use disposable

Strengths:

• First FDA PMA-approved AI skin lesion analyzer
• Multispectral imaging (beyond visible light)
• High sensitivity (>95%) in clinical trials

Weaknesses:

• Commercial failure (too expensive, complex workflow)
• Dedicated hardware (not mobile)
• Discontinued/de-emphasized by STRATA
• No learning capability
• Per-use consumable cost ($150) unsustainable

Lesson for DrAgnes: MelaFind proves that accuracy alone is insufficient. Workflow integration, cost, and usability are equally critical. DrAgnes must be easy, affordable, and mobile.

Competitive Matrix

Feature	DrAgnes	SkinVision	MoleMap	MetaOptima	Canfield	Google Health	3Derm
Dermoscopy support	Native	No	Clinic only	Yes	Yes	No	No
Mobile/phone-based	Yes	Yes	No	Partial	No	Yes	Yes
Offline capable	Yes (WASM)	No	No	No	No	No	No
Continuous learning	Yes (Brain)	No	No	No	No	No	No
Cross-practice learning	Yes (Brain)	No	No	No	No	No	No
FDA cleared	Target 2028	No	N/A	No	Imaging only	No	Yes
HIPAA compliant	Yes	N/A	N/A	Unclear	Yes	No	Yes
Cryptographic provenance	Yes (SHAKE-256)	No	No	No	No	No	No
Differential privacy	Yes (epsilon=1.0)	No	No	No	No	No	No
EHR integration	Planned Phase 2	No	No	Select	Select	No	Unknown
Practice-adaptive	Yes (LoRA)	No	No	No	No	No	No
Open architecture	Yes	No	No	No	No	No	No
Whole-body mapping	Planned Phase 2	No	Yes	Yes	Yes (VECTRA)	No	No
7-point checklist auto	Yes	No	No	Yes	No	No	No
Cost to practice	Low (SaaS)	N/A (consumer)	High (per visit)	Medium (SaaS)	Very High	Free	Enterprise
Melanoma sensitivity	>95% target	~80-85%	Expert-dependent	~87-92%	N/A	~80%	Not public

DrAgnes Unique Value Proposition

What DrAgnes Does That Nobody Else Does

1. Learns From Your Practice: SONA MicroLoRA adapts the base model to your patient population. A practice in equatorial Nigeria seeing high rates of acral melanoma gets a model tuned for that distribution. A Scandinavian practice seeing mostly fair-skinned patients with superficial spreading melanoma gets a different adaptation. No competitor offers this.

2. Learns From Everyone (Privately): The pi.ruv.io brain aggregates de-identified knowledge from all participating practices. This is not federated learning (which averages models) -- this is knowledge graph enrichment where each diagnosis strengthens connections in a semantic graph. The knowledge is richer than any single model.

3. Runs Offline: The WASM-compiled CNN runs entirely in the browser. No internet, no cloud, no latency. Classify a lesion on a hiking trail, in a rural clinic with no connectivity, or in a disaster zone. No competitor can do this.

4. Cryptographic Provenance: Every classification carries a SHAKE-256 witness chain proving which model version, brain state, and input produced it. For FDA audits, malpractice defense, and clinical governance, this is invaluable. No competitor offers this.

5. DermLite-Native: Built specifically for dermoscopic imaging. The preprocessing pipeline, ABCDE automation, and pattern analysis are designed for DermLite's optical characteristics. Consumer apps working from phone photos cannot match dermoscopic accuracy.

6. Open Architecture: Built on open-source RuVector crates. Practices own their data. The model architecture is transparent. Research institutions can validate, extend, and contribute. Vendor lock-in is eliminated.

Positioning Statement

For dermatologists and primary care physicians who need accurate, trustworthy skin lesion classification at the point of care, DrAgnes is an AI-powered dermatology intelligence platform that continuously learns from every participating practice while keeping patient data private. Unlike SkinVision (consumer app, no dermoscopy), MetaOptima (cloud-dependent, static model), and Canfield (expensive hardware), DrAgnes combines DermLite-native dermoscopic analysis with collective brain intelligence, offline WASM inference, and cryptographic provenance to deliver a system that gets smarter with every use and can be trusted in clinical settings.

Market Entry Strategy

Phase 1: Academic Pilot (2026-2027)

• Partner with 3-5 academic dermatology departments
• Publish validation studies comparing DrAgnes to existing tools
• Establish clinical evidence for FDA submission
• Target: JAMA Dermatology, British Journal of Dermatology publications

Phase 2: FDA Clearance + Early Adopters (2027-2028)

• 510(k) submission with 3Derm as predicate
• Launch with 50 early-adopter dermatology practices
• SaaS pricing: $99-199/month/practice (low barrier)
• DermLite partnership for bundled sales

Phase 3: Primary Care Expansion (2028-2030)

• Teledermatology workflow for PCP-to-dermatologist referral
• Integration with major EHR systems
• Target: primary care practices in dermatologist-shortage areas
• Insurance reimbursement partnerships

Phase 4: Global Expansion (2030+)

• CE marking for EU market
• Regional brain instances for data sovereignty
• Multilingual support
• Partnerships with global health organizations for underserved populations